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An Adverse Outcome Pathway (AOP) represents the existing knowledge of a biological pathway leading
from initial molecular interactions of a toxicant and progressing through a series of key events (KEs),
culminating with an apical adverse outcome (AO) that has to be of regulatory relevance. An AOP based on
the mode of action (MOA) of rodent liver tumor promotion by dioxin-like compounds (DLCs) has been
developed and the weight of evidence (WoE) of key event relationships (KERs) evaluated using evolved
Bradford Hill considerations. Dioxins and DLCs are potent aryl hydrocarbon receptor (AHR) ligands that
cause a range of species-speciﬁc adverse outcomes. The occurrence of KEs is necessary for inducing
downstream biological responses and KEs may occur at the molecular, cellular, tissue and organ levels.
The common convention is that an AOP begins with the toxicant interaction with a biological response
element; for this AOP, this initial event is binding of a DLC ligand to the AHR. Data from mechanistic
studies, lifetime bioassays and approximately thirty initiation-promotion studies have established dioxin
and DLCs as rat liver tumor promoters. Such studies clearly show that sustained AHR activation, weeks or
months in duration, is necessary to induce rodent liver tumor promotion e hence, sustained AHR
activation is deemed the molecular initiating event (MIE). After this MIE, subsequent KEs are 1) changes
in cellular growth homeostasis likely associated with expression changes in a number of genes and
observed as development of hepatic foci and decreases in apoptosis within foci; 2) extensive liver toxicity
observed as the constellation of effects called toxic hepatopathy; 3) cellular proliferation and hyperplasia
in several hepatic cell types. This progression of KEs culminates in the AO, the development of hepa-
tocellular adenomas and carcinomas and cholangiolar carcinomas. A rich data set provides both quali-
tative and quantitative knowledge of the progression of this AOP through KEs and the KERs. Thus, the
WoE for this AOP is judged to be strong. Species-speciﬁc effects of dioxins and DLCs are well known e
humans are less responsive than rodents and rodent species differ in sensitivity between strains.
Consequently, application of this AOP to evaluate potential human health risks must take these differ-
ences into account.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The source-to-outcome pathway sequence consists of release,
transport, contact, absorption, dose, molecular interactions, cellularncil, 700 2nd St N.E., Wash-
om (R.A. Becker).
evelopment, National Center
Inc. This is an open access article uresponses, tissue and organ changes, culminating in an adverse
effect (Sobus et al., 2011). An adverse outcome pathway (AOP)
(Ankley et al., 2010) is a subset of the source to outcome sequence.
An AOP, by convention, starts at the molecular interaction step, in
which a xenobiotic chemical moiety interacts with biological
molecule and proceeds to an adverse outcome (AO) via a series of
Key Events (KEs). The sequence of the hierarchical AOP framework
(see SF1 in Supplemental Material), and guidance on the develop-
ment and evaluation of AOPs has been developed (OECD, 2013;
OECD, 2014). Ideally, an AOP will be applicable to a broadnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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common pathway or to have KEs in common. However, the OECD
AOP program (OECD, 2013) permits submission of an AOP case
study applicable to a single chemical, or a very limited number of
chemicals, recognizing that, data permitting, such an AOP may be
expanded in the future to cover a category of chemicals.
Themolecular initiating event (MIE) is a fundamental concept of
all AOPs (Ankley et al., 2010). The MIE has been operationally
deﬁned as the ﬁrst key event (KE) and necessary but not sufﬁcient
to produce the AO. Other KEs within a Mode of Action (MOA) are
deﬁned similarlydnecessary but not sufﬁcient for the AO to occur
(Julien et al., 2009; Simon et al., 2014; USEPA, 2005). Although it
can be argued that initial molecular interactions such as absorption
or parent compound interaction with an enzyme that leads to
production of a toxicologically-active moiety meet the deﬁnition of
an MIE, these events are considered to be upstream of an MIE. The
MIE, by convention (OECD, 2014), “involves a chemical interaction
(e.g., a reaction, covalent binding, hydrogen bonding, electrostatic
interaction, etc.) between a chemical stressor and chemically
deﬁned biomolecules within an organism.” Identifying the MIE as
the ﬁrst KE within the AOP and thus distinguishing it from early
upstream events within the source-to-outcome pathway is
important, especially when adverse outcomes require chronic
exposure and dose-dependent transitions (Patlewicz et al., 2013).
Hence, Patlewicz et al. (2013) introduced the idea of the “Initial
Molecular Event” (IME) to capture necessary biological responses
that are chemically induced early on in the pathway but may not be
sufﬁcient to “initiate” an adverse outcome. Drewe et al. (2014) used
the term pre-MIE to make the same distinction. These alternative
constructs reﬂect concern that some would infer certainty of an
adverse outcome based solely on responses from assays associated
with an MIE. In this AOP, we use the term pre-MIE.
Within an AOP, the MIE is followed by one or more intermediate
KEs, which are connected in a sequential and integrated manner,
culminating in the AO (Andersen et al., 2014). A Key Event Rela-
tionship (KER) “connects one key event to another, deﬁnes a
directed relationship between the two (i.e., identiﬁes one as up-
stream and the other as downstream), and facilitates inference or
extrapolation of the state of the downstream key event from the
known, measured, or the predicted state of the upstream key event”
(OECD, 2014). In other words, a KER captures the knowledge of the
toxicodynamic relationship between KEn and KEnþ1, and this
knowledge may be sufﬁcient to develop a prediction model. KERs
necessarily include homeostatic mechanisms, and therefore, un-
derstanding dose-dependent transitions and tipping points along
the sequence of KEs is important when developing, evaluating and
applying AOPs. Further, responses can be inﬂuenced by co-exposure
to other substances, and these components are referred to as
modulating factors when considered within a MOA (Andersen et al.,
2014); modulating factors affect the nature of KE doseeresponse
relationships. Associative events serve as reliable biomarkers or
indicators of KE(s) but may not be causal themselves. Thus, one
needs to consider exposure pathways, chemical properties, ADME,
modulating factors, and associative events when developing and
applying AOPs (Carmichael et al., 2011; Dellarco and Fenner-Crisp,
2012; Fenner-Crisp, 2012; Julien et al., 2009). Beneﬁting from
experience gained from over the last 2e3 years, largely through the
OECDAOP program (OECD, 2014) and the AOPWiki (USEPA, 2014), a
component of the OECD-sponsored AOP Knowledgebase, recent
publications provide greater clarity with respect to the concepts of
KEs, KERs, (Villeneuve et al. (2014a, 2014b), strategies and practices
to use when developing AOPs. Scientiﬁc conﬁdence in the identiﬁ-
cation of KEs and in KERs may be judged using the evolved Bradford
Hill (BH) considerations (Hill, 1965; Meek et al., 2013, 2014a, 2014b;
OECD, 2014; Patlewicz et al., 2015; Becker et al., 2015).In constructing AOPs, OECD recognizes the importance of
initially drawing upon case examples applicable to a single chem-
ical or a limited number of chemicals (OECD, 2015). The goal of
these case examples is to expand the AOP concept to a broader
chemical domain as experience and knowledge is gained. Consis-
tent with this goal, we have chosen to draw from the MOA of aryl
hydrocarbon receptor (AHR) activation causing liver tumors in ro-
dents, including the extensive of knowledge of the biological pro-
cess of rodent liver tumorigenesis (Budinsky et al., 2014). In the
following case study, we describe the AOP of sustained AHR acti-
vation leading to rodent liver tumor promotion. This AOP case
study forms a project within the OECD AOP work program and is
also being summarized for inclusion into the AOP Wiki. The sus-
tained AHR activation rodent liver tumor promotion AOP is shown
in Fig. 1, organized according to the OECD AOP template.
The MIE is identiﬁed as sustained activation of the AHR pro-
duced by biologically persistent dioxin-like chemicals (DLCs). DLCs
are potent AHR ligands that cause a range of species-speciﬁc
adverse outcomes (Okey, 2007). The role of the AHR in carcinoge-
nicity has been extensively studied and reviewed (Beebe et al.,
1995; Bock and Kohle, 2005; Gasiewicz et al., 2008; Goodman
and Sauer, 1992; Hailey et al., 2005; Knerr et al., 2006; Kociba
et al., 1978; Stinchcombe et al., 1995). A number of cancer bio-
assays demonstrate that such compounds can induce hepatocel-
lular adenomas/carcinomas and cholangiomas/carcinomas in
various test species (Table 1) (Della Porta et al., 1987; Kociba et al.,
1978; NTP, 1980; NTP, 1982a; NTP, 1982b; NTP, 2006a; NTP, 2006b;
NTP, 2006c; NTP, 2006d; NTP, 2006e; NTP, 2006f; NTP, 2010).
Approximately thirty initiation-promotion studies provide a com-
plement to these cancer bioassays and, together have established
the mechanism by which dioxin and DLCs act as rodent liver tumor
promoters. Initiation-promotion studies rely on an initiating agent,
generally diethylnitrosamine, to increase the population of initiated
liver cells. Following initiation, treatment with DLCs or other tumor
promoters, with or without partial hepatectomy, promotes the
development and growth of pre-neoplastic altered hepatic foci.
When treatment with promoters is continued for a sufﬁcient time
and dose, tumor formation occurs (Buchmann et al., 1994; Dragan
et al., 1992; Maronpot et al., 1993; Teeguarden et al., 1999).
The mechanistic causal link between earlier histopathological
KEs in liver and tumor development likely resides in the prolifer-
ative potential of the liver and the ability of this organ to regenerate
following cytotoxicity (e.g., Cohen and Ellwein, 1990; Cohen and
Arnold, 2011; Tomasseti and Vogelstein, 2015). Replacement of
damaged hepatocytes may occur through replication of neigh-
boring hepatocytes or, if damage is extensive, through recruitment
of liver stem cells (Alison, 2005; Pintilie et al., 2010; Tanaka et al.,
2011; Wang et al., 2003; Wolﬂe et al., 1993). Although DLCs have
also been reported to cause tumors of the lung and oral mucosa in
rodents, these tumor types are not considered further since they
are outside the scope of this AOP (NTP, 2006a; NTP, 2006b; NTP,
2006c; NTP, 2006d; NTP, 2006e; NTP, 2006f; NTP, 2010; Wang
et al., 2011).
Each component and KE of the AOP is discussed below in greater
detail and in temporal sequence. As is the case for all AOPs, as
further research increases knowledge of the mechanism of action
(detailed molecular events and cellular processes), the KEs and
KERs for sustained AHR activation leading to rodent liver tumor
promotion are likely to evolve; the online AOPWiki is well suited to
accommodate such an evolution.
2. Toxicant (chemical properties)
Co-planar halogenated polyaromatic hydrocarbon structures
with halogens in speciﬁc locations bind to and activate the AHR,
Fig. 1. Schematic of the sustained AHR activation rat liver tumor promotion AOP showing the molecular initiating event (MIE), intermediate key events (KE) and the adverse
outcome (AO).
Table 1
Summary of key chronic tumor bioassays in rodents treated with TCDD.
Study Dose (ng/kg-day) and liver tumors
Rats
Kociba et al., 1978; Spartan Sprague Dawleya 0 1 10 100
Female 2/86 1/50 9/50 18/45
Male 2/85 0/50 0/50 1/50
NTP, 1982; Osborne Mendelb 0 1.4 7.1 71
Female 5/75 1/49 3/50 14/49
Male 0/74 0/50 0/50 3/50
NTP, 2006; Harlan Sprague Dawley 0 2.1 7.1 16 33 71
Female Only
Cholangiolarcarcinoma 0/53 0/54 0/53 1/53 4/53 25/53
Adenoma 0/53 0/54 0/53 0/53 1/53 13/53
Hepatocholangioma 0/53 0/54 0/53 0/53 0/53 2/53
Mice
NTP, 1982; B6C3F1b 0 6.7 67 330
Female 3/73 6/50 6/48 11/47
0 1.7 8.3 83
Male 15/73 12/49 13/49 27/50
Della Porta et al., 1987; B6C3 0 150 360
Femalec 3/49 16/42 20/48
0 160 360
Malec 15/43 26/51 43/50
a Number of animals with tumors/total number of animals in the study.
b Number of tumor-bearing animals/number of animals examined at site; neoplastic nodule or hepatocellular carcinoma.
c Combined liver carcinoma and adenoma.
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polychlorinated dibenzofurans (PCDFs), polychlorinated naphtha-
lenes (PCNs), co-planar polychlorinated biphenyls (PCBs) and pol-
yaromatic hydrocarbons (PAHs). A few structure-activity models
have been published for PCDDs/PCDF/dioxin-like PCB interactions
(Petkov et al., 2010; Zhao et al., 2008). 2,3,7,8-Tetrachlorodibenzo-
p-dioxin (TCDD) is the most potent AHR agonist in the group of the
bicyclic halogenated dioxins and furans. Several other DLCs possess
potency within an order of magnitude of TCDD; these include other
PCDDs, PCDFs and certain PCBs (Van den Berg et al., 2006). This
structural requirement for co-planarity with halogens in the
2,3,7,8-position is an important component of the toxic equivalency
factor (TEF) approach for risk assessment for mixtures of PCDDs
and PCDFs and reﬂects the relative binding afﬁnity of these com-
pounds to the AHR (Van den Berg et al., 2006). A number of PCDD,
PCDF and PCB congeners have been shown to promote clonal
expansion of altered hepatic foci in rodent liver standard initiation-
promotion protocols or to induce liver tumors in 2-year cancer
bioassays in both mice and rats (reviewed in Budinsky et al., 2014).
Because the AHR is a highly promiscuous receptor,understanding the structural features associated with potency of
AHR activation is, at best, rudimentary. AHR ligands include a
plethora of chemically divergent anthropogenic, natural and
endogenous molecules with widely diverse structural features
(Denison and Nagy, 2003; Denison et al., 2011; Hu et al., 2013;
Nguyen and Bradﬁeld, 2008). Extant knowledge of the ligand-
binding domain of the AHR is not yet sufﬁcient to predict
whether a ligand acts an agonist, antagonist, or a modulator.
Therefore, except for the DLCs, predicting whether an AHR ligand
will act as a rodent liver tumor promoter is not yet possible.
Summarizing the chemical properties shared by the plethora of
AHR ligands presents a challenge e the large diversity of AHR li-
gands complicates the development of predictive structural alerts.
Hence, using a QSAR approach to understand the biological activity
of AHR ligands is currently not possible, other than for PCDDs,
PCDFs and coplanar PCB congeners which share obvious structural
features. In time, structural alerts for the tumor promoting poten-
tial of the constellation of AHR ligands may be identiﬁed (ST1
Supplemental Material)). However, because of the promiscuity of
the AHR, structural features alone may be insufﬁcient to rule in or
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ligands may not be correctly identiﬁed in a QSAR screen (Denison
et al., 2011; Herrmann et al., 2002).
3. Macromolecular interactions and ligand-activation of
transcription: Pre-MIE and MIE events
The AHR is a ligand-activated transcription factor that belongs
to the Per-Arnt-Sim (PAS) family of proteins (Kumar et al., 2001;
Partch and Gardner, 2010; Soshilov and Denison, 2011). The AHR
and a number of other nuclear receptor proteins control a wide
range of cellular responses through alterations in gene expression.
AHR-directed transcription (F2 Supplemental Material) has been
extensively investigated (Abel and Haarmann-Stemmann, 2010;
Dietrich and Kaina, 2010; Furness and Whelan, 2009; Gasiewicz
et al., 2008).
In the absence of ligand binding and activation, the AHR resides
in the cytosol complexed to its chaperone proteins, Hsp90, AIP and
p23 proteins. The AHR interacts with other transcription factors,
including the estrogen receptor, the glucocorticoid receptor, the
mitochondrial protein ATP5a1 (Denison et al., 2011; Matthews and
Gustafsson, 2006; Sato et al., 2013; Tappenden et al., 2013).
Following ligand binding, the AHR sheds the chaperones and binds
to the aryl hydrocarbon receptor nuclear translocator or ARNT,
another protein in the PAS family. The liganded AHR-ARNT dimer
binds to dioxin response elements on DNA. A number of co-
regulatory proteins bind to the transcription complex to provide
unique cell and ligand-speciﬁc transcriptional outcomes (Beischlag
et al., 2008; George et al., 2011; Kumar et al., 2004; Lee and Lee
Kraus, 2001; Lees and Whitelaw, 1999; Perissi and Rosenfeld,
2005; Reen et al., 2002; Tsai and Fondell, 2004). Ubiquitin-
mediated proteolysis of the AHR serves to inactivate the receptor
complex.
Gene expression changes induced by AHR activation occur
within hours (Matthews et al., 2005). However, AHR activation
must be sustained for a signiﬁcant portion of the rodent lifespan for
tumor formation to occur (NTP, 2006a; NTP. 2006b; NTP, 2006c).
Therefore, what may be critical in distinguishing between these
acute and sustained effects is knowledge of the constellation of
macromolecular events that transpire on both timescales e hours
to days for acute effects versus several months up to a year for
sustained AHR activation.
The genomic changes induced by DLCs can be organized into
two categories. The ﬁrst is the rapid induction of a core battery
genes consisting of a number of drug metabolizing enzymes and
the second consists of changes in the expression of other genes that
are temporally concordant with the critical histopathological KEs
leading to promotion of liver tumors (Ovando et al., 2006; Vezina
et al., 2004).
3.1. Core battery response
These genomic changes are adaptive responses and provide
several reliable biomarkers of AHR activation (Boutros et al., 2004,
2009, 2011; Boverhof et al., 2005; Boverhof et al., 2006).
The induction of CYP1A1 expression measured by
ethoxyresoruﬁn-O,O-deethylase is a common marker of AHR acti-
vation and remains elevated for at least one year with sustained
administration of DLCs (NTP, 2006a; NTP, 2006b; NTP, 2006c; NTP,
2006d; NTP, 2006e; NTP, 2006f; NTP, 2010). The induction of
CYP1A1, part of the core battery response, is used here as an
associative event or biomarker for AHR activation.
The one consistent and well-accepted transcriptional response
to AHR activation involves the core battery response that is rep-
resented by the induction of a number of important xenobioticmetabolic enzymes (CYP1A1, CYP1A2, Cyp1B1, UGT1A isoforms,
Nqo1, and GST) (Rowlands et al., 1996). In-vivo and in-vitro genomic
data on both short-term and chronic time scales reﬂect the
response of parenchymal cells to AHR activation to a greater extent
than other liver cell types. AHR activation results in the up- and
down-regulation of hundreds of genes (Black et al., 2012; Boutros
et al., 2011; Boverhof et al., 2006; Brauze and Rawłuszko, 2012;
Carlson et al., 2009; Fletcher et al., 2005; Forgacs et al., 2010;
Franc et al., 2008; Heise et al., 2012; Le Vee et al., 2010; Ma et al.,
2001; Moffat et al., 2010; Ovando et al., 2006, 2010; Rowlands
et al., 2011; Vezina et al., 2004; Yao et al., 2012). These data
potentially offer insights into pathways and signaling networks
that might be important contributors to this AOP. For example, Nrf2
induction is part of an antioxidant response pathway and is induced
by AHR activation (Wang et al., 2013). Induction of Nrf2 appears to
provide protection against TCDD-induced steatosis (Lu et al., 2011).
Induction of Nrf2 protects against the effects of other liver carcin-
ogens (Ikeda et al., 2004; Jaramillo and Zhang, 2013; Kwak et al.,
2001; Liby and Sporn, 2012; Ma and He, 2012; Osburn et al.,
2008; Shelton and Jaiswal, 2013; Yates and Kensler, 2007; Yates
et al., 2007). Since these core battery responses may not be
directly linked to toxicity they may best serve as biomarkers and
hence, associative events, applicable for quantitative modeling of
AHR activation (Andersen et al., 2014; Budinsky et al., 2010, 2014;
Julien et al., 2009; Simon et al., 2014).
3.2. Other gene expression changes
AHR activation results in transcription changes in many genes
beyond the core battery response. TiPARP is induced by TCDD and
may act to enhance ubiquitinization of proteins (Ma et al., 2001).
Stearoyl coenzyme A desaturase 1 (Scd-1) is involved in fatty acid
metabolism andmay be involved in dioxin-induced steatosis; Scd-1
is downregulated after 52 weeks of TCDD treatment in Sprague
Dawley Female rats but upregulated in immature mice following
acute TCDD exposure (Angrish et al., 2011; Ovando et al., 2010).
Different strains of rats possess varying degrees of dioxin sensi-
tivity; the dioxin-resistant Hans Wistar kupio strain has a major
deletion of the transactivation domain of the AHR and fewer gene
expression changes occur in this strain in response to high doses of
TCDD (Boutros et al., 2011).
At present, a clear and consistent transcriptional signal
following acute or short-term AHR activation across strains and
species is not apparent. Early transcriptional changes so far
measured in rats vary across strains and are not conserved across
species, e.g., mice vs. rats, humans vs. rats (Angrish et al., 2011;
Black et al., 2012; Ovando et al., 2010; Yao et al., 2012). Relevant
pathways or gene networks cannot be identiﬁed due to the lack of a
consistent transcriptional response (Zhang and Andersen, 2007). In
addition, the predominant transcriptional signal observed in vivo
represents the response of hepatocytes because these cells
comprise the bulk of the liver. Other cell types such as oval/stem
cells, stellate cells, and bile duct cells may be central to the bio-
logical response to sustained AHR activation that leads to tumor
formation (Bendall and Nolan, 2012; Chia and Ng, 2012; Ma, 2011;
Tanaka et al., 2011). However, the transcriptional response of these
other cell types is difﬁcult to measure or observe.
3.3. Gene expression temporally concordant with the critical
histopathological ﬁndings
Ovando et al. (2010) evaluated the 13 and 52 week liver tissues
from the 100 ng/kg/day 2006 NTP TCDD cancer bioassay treatment
group that showed clear evidence of hepatocellular and chol-
angiolar carcinoma. Genes with altered expression at 24 h, 13
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description of the function of each gene (Ovando et al., 2010) are
presented in ST2 Supplemental Material. Histopathology that could
be linked to the MIE was not observed in the livers of rats exposed
for 13 weeks; however, by 52 weeks, the histopathologic observa-
tions were robust and clearly linked to the MIE (Hailey et al., 2005).
Hence, the genomic signals observed at 52 weeks are those
temporally concordant with the occurrence of histopathology.
How do these genomic changes correspond to the genomic
signatures of other non-genotoxic liver carcinogens? A number of
studies have attempted to separate genotoxic from non-genotoxic
hepatocarcinogens based on their genomic signature (Ellinger-
Ziegelbauer et al., 2005, 2008; Fielden et al., 2007; Fielden et al.,
2011; Nie et al., 2006; van Delft et al., 2005; Watanabe et al.,
2012). Nie et al. (2006) reported six gene expression changes as
predictive of non-genotoxic carcinogens after 24 treatment in male
rats; however, no overlap exists between these six and the genomic
changes observed after 52 weeks of DLC exposure. Fielden et al.
(2011) proposed a signature consisting of expression changes in
22 genes for non-genotoxic rat liver carcinogens, and the training
set included TCDD; only a few of these genes were reported as
having altered expression in the livers of the rats in the NTP bio-
assays at 13 or 52 weeks (Ovando et al., 2010). Whether consistent
patterns of gene expression changes and pathways can be linked to
established KEs, associative events and modulating factors remain
to be determined.3.4. MIEdSustained AHR activation
Insight into sustained AHR activation is provided by examining
the induction of ethoxyresoruﬁn-O,O-deethylase in liver by three
DLCs at three different time points (NTP, 2006a; NTP, 2006b; NTP,
2006c). Plots of the fractional or normalized ethoxyresoruﬁn-O,O-
deethylase response from three NTP cancer bioassays are shown in
the plots on the left of Fig. 2. Induction of ethoxyresoruﬁn-O,O-
deethylase is easily measured and serves as a marker of CYP1A1
gene expression. The dose term on the x-axis is the area under the
curve (AUC) of liver concentration. The normalized
ethoxyresoruﬁn-O,O-deethylase response on the y-axis is similar
at 14, 31 and 53 weeks (Left column of Fig. 2). The plots for 31
weeks and 53 weeks are shifted to the right given the dose term on
the x-axis is the AUC of hepatic concentration of the three chem-
icals, TCDD, 4-PeCDF and PCB-126. To obtain a measure of sus-
tained AHR activation, the fractional ethoxyresoruﬁn-O,O-
deethylase response is multiplied by the number of weeks.
Hence, a fractional response of 50% at 14 weeks would be a sus-
tained AHR activation index of 7. The sustained AHR activation
index is plotted versus the AUC of hepatic toxic equivalents (TEQ)
for all three chemicals calculated using TEF values of 1.0, 0.3 and
0.1 for TCDD, 4-PeCDF and PCB-126 respectively (Van den Berg
et al., 2006) (Fig. 2, right column). The sustained AHR activation
index shows a strong relationship to the AUC of hepatic TEQ and
thus the sustained AHR activation index reﬂects the dose, potency
and duration of DLCs in the liver.
Dose-response modeling can be performed using the sustained
AHR activation index as the dose term and the measures of the
various KEs or biomarkers as the response. Fig. 4 shows an example
in which the well-known Hill doseeresponse model was used. One
of the model parameters is the ED50 or EC50 value e in other
words, the effective dose or concentration sufﬁcient to produce a
50% of the maximal response. This parameter is also called the half-
maximal dose. When this measure of sustained AHR activation is
used, the ESA50 denotes the level of sustained AHR activation
required for a half-maximal response.4. Cellular responses associated with KEs
AHR activation results in cellular responses that range from
transcriptional changes to alterations in biochemical pathways that
ultimately impact cellular function. These changes are dose- and
time-dependent and range from adaptation to toxicity.4.1. KE #1: changes in cellular homeostasis and decreased apoptosis
in hepatic foci and/or damaged hepatocytes
Tumor promotion requires a perturbation in the balance be-
tween cell gain via mitosis and cell loss via apoptosis (Roberts et al.,
1997). Indirectly, the inhibition of apoptosis in either damaged or
initiated cells favors their survival, and inhibition of apoptosis af-
fords initiated cells an increased opportunity for clonal expansion
and autonomous growth with the chance to acquire additional
mutations during the process of tumor progression. AHR activation
inhibits apoptosis in altered hepatic foci (i.e., initiated hepatic cells),
and this inhibition affords cells within altered hepatic foci a sur-
vival advantage and increases the likelihood that these cells will
acquire additional mutations.
TCDD inhibited apoptosis in altered hepatic foci (Luebeck et al.,
2000; Paajarvi et al., 2005; Schrenk et al., 1994, 2004;
Stinchcombe et al., 1995). For this KE, initiation-promotion
studies provide indirect evidence of inhibition of intrafocal
apoptosis due to sustained AHR activation and direct evidence of
a threshold for the clonal expansion of altered hepatic foci
(Dragan and Schrenk, 2000; Teeguarden et al., 1999). Although
increases of cell proliferation could contribute to the increase in
size and volume fraction of altered hepatic foci, the greater
magnitude of inhibition of apoptosis suggests it is the primary
factor contributing to clonal expansion of altered hepatic foci, at
least early on (Luebeck et al., 2000; Moolgavkar et al., 1996;
Stinchcombe et al., 1995). TCDD inhibits apoptosis produced by
UV light exposure of human cell lines and rat primary hepatocytes
(Ambolet-Camoit et al., 2010; Chopra et al., 2009, 2010; Schwarz
et al., 2000). Inhibition of apoptosis in primary rat hepatocytes
was mediated through phosphorylation and inactivation of p53
and modulation of Mdm2, Tfgb1/4, and AGR2; in addition, inhi-
bition of apoptosis required protein synthesis (Ambolet-Camoit
et al., 2010; Chopra and Schrenk, 2011; Chopra et al., 2009,
2010; Davis et al., 2001; Franc et al., 2008; Paajarvi et al., 2005;
Worner and Schrenk, 1996, 1998). Cytotoxicity appears to occur
after intrafocal apoptosis inhibition is measured and
inﬂammation-driven cell proliferation is a somewhat later event.
What remains unknown is whether a proliferative response in
stem and stellate cells occurs earlier or at the same time as
intrafocal apoptosis inhibition.
The growth of altered hepatic foci is highly related to tumor
formation. The relationship of the MIE to this KE is illustrated
schematically in Fig. 3. When the increase in volume fraction in
altered hepatic foci is plotted versus the MIE measured by the
sustained AHR activation index, a threshold is apparent at a sus-
tained AHR activation index in the range of 5e10 (Fig. 3B).5. Organ-level response
Pre-neoplastic histopathological changes represent a signiﬁcant
organ-level KE following sustained AHR activation and necessary
for tumor promotion (Goodman and Sauer, 1992; Hailey et al.,
2005). Quantitative doseeresponse modeling of the events
included in toxic hepatopathy provides a path to understanding the
AOP (Fig. 4).
Fig. 2. Measuring sustained AHR activation (SAA). Left: EROD (ethoxyresoruﬁn-O-deethylase) responses of three DLCs at 14, 31 and 53 weeks in the NTP cancer bioassays in
response the hepatic AUC (2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD); 2,3,4,7,8-pentachlorodibenzofuran (4PeCDF); 3,30 ,4,40 ,5-Pentachlorobiphenyl (PCB 126)). Right: Combined
responses of all chemicals expressed as AUC of hepatic TEQ. All curves were ﬁt with Hill model implemented in Graphpad Prism.
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As deﬁned in NTP (2006a), toxic hepatopathy consists of a
constellation of different histological observations including, but
not limited to, hepatocyte hypertrophy, multinucleated hepato-
cytes, inﬂammation, pigmentation, steatosis, portal ﬁbrosis, bile
duct cysts, cholangioﬁbrosis, mitochondrial injury, necrosis,
ﬁbrosis, and porphyria, as well as bile duct and oval cell hyperplasia
(Boverhof et al., 2005; Chang et al., 2005; Hailey et al., 2005; Jones
and Greig, 1975; NTP, 2006; NTP, 2006; NTP, 2006; NTP, 2006; NTP,
2006; NTP, 2006; NTP, 2006; Walker et al., 2006; Simon et al.,
2009).
For the purpose of distinguishing KE#2 from KE#3, KE#2 is
considered to represent the effects included in hepatopathy
without bile duct hyperplasia and oval cell hyperplasia. Transitionaldose values as a measure of possible thresholds for toxic hepat-
opathy, bile duct hyperplasia and oval cell hyperplasia in units of
the sustained AHR activation index are shown in Table ST3
(Supplemental Materials). This value for hepatopathy is consider-
able lower than those for bile duct hyperplasia or oval cell hyper-
plasia and thus, support the idea that toxicity and proliferation are
distinct KEs.
The relationship of this constellation of organ-level effects to
hepatocellular cancer is well established in mammalian species; for
example, steatosis and nonalcoholic steatohepatitis increase the
risk of liver cancer in humans and rodents (Ip and Wang, 2014;
Nakamura and Terauchi, 2013). Sustained AHR activation induces
steatosis and could act in a similar fashion.
Necrosis and inﬂammation are not observed after 52 weeks of
DLC administration but occur during the second year of treatment
Fig. 3. Rat liver tumor promotion by persistent AHR ligands. A) Simpliﬁed diagram showing changes in both cell proliferation and apoptosis appear to promote tumors. B) Plot of the
increase in volume fraction of ATPase-deﬁcient hepatic foci versus sustained AHR activation (SAA) index. Data from Teeguarden et al. (1999). The Hill model was used to ﬁt the data
and implemented in Graphpad Prism.
R.A. Becker et al. / Regulatory Toxicology and Pharmacology 73 (2015) 172e190178and are observed at the 2-year termination of the NTP cancer
bioassays. Necrosis and inﬂammation are observed at lower doses
than those at which tumors were observed (Hailey et al., 2005).
Damage to hepatocytes and cytotoxicity are common features of
these histopathological changes. This provides empirical support
for the hypothesis that regenerative repair may be a contributor to
the proliferative response and the adverse effects observed at the
higher TCDD dosages.
The quantitative KER linking the MIE to KE#2 is shown in the
top panel of Fig. 4A. Usingmethods described in Simon et al. (2014),
the transitional dose values of the sustained AHR activation index
based on a 21% response level are shown in ST3 Supplemental
Material. Here, the transitional dose value is the projection from
the 21% response level to the background response level using the
slope of the doseeresponse at this same 21% response level (Sand
et al., 2006; Simon et al., 2014). While not deﬁnitive thresholds,
transitional dose values based on the 21% response level can be
used as an approximation of a threshold. As noted, toxic hepatop-
athy includes a constellation of effects and the transitional dose
value has the lowest value of the three effects representing the
toxicity of KE#2 and the proliferation/hyperplasia of KE#3.
ESA50 (Fig. 4) is similar to an EC50 e it is the effective level of
sustained AHR activation necessary to achieve a 50% response. As
described, the level of sustained AHR activation can be calculated
by multiplying the fractional level of AHR activation measured by
CYP1A1 induction by the number of weeks of dosing (Fig. 2B). Bile
duct hyperplasia occurs at a higher level of sustained AHR activa-
tion and oval cell hyperplasia at an even higher level (Fig. 4A,
middle and bottom plots). The doseeresponse for oval cell hyper-
plasia is much steeper than the other two histopathological effects
that comprise KE#3. Although speculative, this higher level of
sustained AHR activation needed for bile duct hyperplasia may be
the reason why Kociba et al. (1978) failed to observe bile duct tu-
mors whereas they were observed in NTP (2006a). Possibly, the
distinction between the two studies may be that dosage regimen
(diet vs. gavage) or changes in the SpragueeDawley strain over
time. In the rats used in Kociba et al. (1978), the degree of sustained
AHR activation needed for promotion of bile duct tumors may not
have been achieved.
5.2. KE#3: altered proliferation and hyperplasia of hepatocytes,
stem cells and other cell types in the liver
Over the time period of high levels of sustained AHR activation,
DLCs produce a complex pattern of cell proliferative responses.
Teeguarden et al. (1999) observed that rats initiated withdiethylnitrosamine (DEN) and then dosed with either 0.1 or 1 ng/
kg-d TCDD for one month exhibited a reduced labeling index
relative to controls, and reduced BrdU-labeling was also observed
following the 0.1 ng/kg-d TCDD dose after three months. Maronpot
et al. (1993) observed a reduction in BrdU labeling index in hepa-
tocytes at a low dose of 3.5 ng/kg-d TCDD in DEN-initiated rats after
30 weeks of TCDD administration but, at a dose of 125 ng/kg/d the
labeling index was increased.
Both parenchymal calls and liver stem cells are likely involved in
the organ-level response to sustained AHR activation. Early acti-
vation of the AHR in zone 3 of the liver acinus causes decreased
hepatocyte replication and may act as an indirect proliferative
stimulus for stem cells and hepatoblasts (Andersen et al., 1997;
Conolly and Andersen, 1997; Tritscher et al., 1992). Oval cells in
the periportal region likely function as a source of replacement of
hepatocytes after inhibition of normal hepatocyte replication-
replacement (Paku et al., 2001; Sahin et al., 2008; Tanaka et al.,
2011; Wang et al., 2003). While hepatocyte replication is consid-
ered the normal means for replacement of liver parenchyma, in-
hibition of hepatocyte replication in centrilobular regions induced
by TCDD may induce normally quiescent liver stem cells to
proliferate.
Following longer period of sustained AHR activation, organ-
level increases in cell proliferation ensue, demonstrated by an in-
crease in BrdU labeling and likely reﬂecting the regenerative
response to organ-wide toxicity (Hailey et al., 2005).
Non-parenchymal cells, including stem cells, hepatoblasts,
biliary cells, stellate cells, endothelial cells, and Kuppfer cells, play a
role in this AOP. In rodents, TCDD elicits a ﬁbrogenic and bile duct
proliferative response that requires pathological alteration of stel-
late cell function and increased differentiation and growth of
hepatoblasts and bile duct cells before 33 weeks of exposure.
Retinoid depletion induces stellate cell proliferation, production of
extracellular matrix components, and the transition to ﬁbroblast;
stellate cells maintain vitamin A homeostasis and respond to liver
injury with formation of proliferative cytokines such as TGF-a and
EGF (Friedman, 2008; Pintilie et al., 2010; Senoo et al., 2010). TCDD
induces loss of retinoid content (presumably from stellate cells) and
may disrupt the extensive communication between various liver
cell types (Fletcher et al., 2001; Hoegberg et al., 2005; Pierre et al.,
2014; Schmidt et al., 2003). Thus, TCDD-induced retinol loss from
hepatic stellate cells may contribute to cell proliferation, biliary
ﬁbrosis, and cholangiolarcarcinoma (Fattore et al., 2000; Friedman,
2008; Hakansson and Hanberg, 1989; Schmidt et al., 2003).
AHR activation also induces changes in stem/oval cells. All of the
rats receiving 100 ng/kg/day TCDD, the highest dose group animals
Fig. 4. Indirect key event relationships. Sustained AHR activation was identiﬁed as the MIE and determined as the product of fractional AHR activation measured by CYP1A1
induction and time in weeks. The frequency of histopathology and tumors observed in rats in the NTP bioassays was plotted against sustained AHR activation. A) Relationships
between the MIE and aspects of KE2 (hepatopathy and hyperplasia; all response shown as ﬁlled circles). B) Relationships between the MIE and the two tumor types representing the
adverse outcome (AO) (responses shown as an X). The Hill coefﬁcients, BMD21 and TDV21 values are shown in ST3 Supplemental Material. The values shown as open circles in the
two plots in B show tumor responses in animals in the stop-exposure group that were exposed to the maximum DLC concentration for 31 weeks (see text for discussion). In each
plot in B, three values, one each for TCDD, 4-PeCDF and PCB-126, are shown for the stop-exposure experiments and only two are not obscured by the other responses. The numerical
ESA50 values are the half-maximal level of sustained AHR activation similar to an EC50 and described in the text.
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clear statistical increases in this endpoint at 22 ng/kg/day or greater
(Hailey et al., 2005).
Evidence points to the involvement of TNF-a regulation in the
proliferative response of hepatic stem cells; this is likely mediated
through modulation of the levels of TNF-a, altered b-catenin
signaling, and inhibition of cell-to-cell contact (Knight et al., 2000;
Umannova et al., 2007; Vondracek et al., 2009; Dietrich et al., 2002;
Prochazkova et al., 2011; Prochazkova et al., 2011; Weiss et al.,
2008). TNF-a is an inﬂammatory cytokine with an important role
in liver tumor promotion. More research on how sustained AHR
activation dysregulates normal TNF-a activity could be very im-
pactful on evolving the AOP.5.3. Adverse outcome: hepatocellular adenoma/carcinoma and
cholangiolar carcinoma in rodents
As well as toxic hepatopathy, the organ-level response includes
the adverse effects of hepatocellular adenomas/carcinomas, and
cholangiocarcinomas as the apical adverse outcomes. Adenomas
may arise from altered hepatic foci that are derived from hepato-
cytes or hepatoblasts whereas hepatocellular carcinomas and
cholangiocarcinomas likely arise from initiated stem cells. How-
ever, the actual cellular origin of the various liver tumor types is not
known with certainty and involvement of both liver stem cells and
hepatocyte-like cells have been observed in hepatocellular ade-
nomas (Libbrecht et al., 2001; Libbrecht, 2006).
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cholangiocarcinomas) occur at a transitional dose value for sus-
tained AHR activation of about 100 (ST3 Supplemental Material).
This would represent maximal or 100% activation of the AHR sus-
tained for 100 weeks. The calculation is borne out by the extremely
steep doseeresponse curves (Fig. 4B). In each of two plots in Fig. 4B,
three open circles (one each for TCDD, 4-PeCDF and PCB-126) show
tumor responses in animals in the stop-exposure group that were
exposed to the maximum DLC concentration for 31 weeks. In these
stop-exposure groups maximal AHR activationwas sustained for 31
weeks, about 30% of the lifespan. The tumor incidence for both
types of tumors in the animals in these stop-exposure groups was
5% or less for both tumor types and not signiﬁcantly increased.
However, the occurrence of tumors indicates that a sustained AHR
activation value of 30 is sufﬁcient for tumor formation, e.g., a point
of departure consideration for anchoring the threshold response.
6. Species speciﬁcity and relevance to humans
Overall, empirical evidence supporting the applicability of this
AOP to humans is absent. Only a single KE has been observed in
humansdbinding and activation of the AHR by DLCs with accom-
panying hepatic CYP1A induction (Abraham et al., 2002; Budinsky
et al., 2010; Coenraads et al., 1999; Lambert et al., 2006; Tang et al.,
2008). For perspective purposes regarding an unequivocal dioxin
effect occurring in highly exposed human subjects, high levels of
AHR activation in humans alter the growth and differentiation of
keratinocytes and produce chloracne (Forrester et al., 2014; Geusau
et al., 2001; Ju et al., 2011; Moses and Prioleau, 1985; Saurat and
Sorg, 2010; Saurat et al., 2012; Sorg, 2014; Sutter et al., 2009,
2010, 2011). In contrast, the epidemiological evidence for TCDD-
associated liver cancer in humans is negative or equivocal
(Akintobi et al., 2007; Bertazzi et al., 1989; Du et al., 2006; Geusau
et al., 2005; Hankinson, 2009; Loertscher et al., 2001). Tri-
chlorophenol workers exposed toTCDD show no increase in liver or
biliary cancer (Collins et al., 2009; McBride et al., 2009). The
occurrence of chloracne indicates high levels of exposure to DLCs
and signiﬁcant AHR activation; even in such cases, no evidence of
liver injury or cancer has been reported (Ghezzi et al., 1982;
Mocarelli et al., 1986, 1991; Pocchiari et al., 1979; Reggiani, 1980).
In other trichlorophenol workers, transient changes in liver enzyme
levels were reported in alcohol consumers only (Calvert et al.,
1992).
The unique Yusho and Yucheng rice oil poisonings are con-
foundeddthe exposures were to a mixture of complex PCBs, pol-
ychlorinated dibenzofurans, and mixtures of quarterphenyl, and
terphenyl compounds. Clearly, these compounds possess dioxin-
like properties and the mixture was sufﬁciently potent to induce
a chloracne-like condition in some individuals (Lambert et al.,
2006). An increase in mortality from cirrhosis and chronic liver
disease has been observed among the victims of the Yusho
poisoning incident, whereas liver cancer was not elevated
(Onozuka et al., 2009). The rate of mortality from chronic liver
disease was increased in men only among the victims of the similar
Yucheng poisoning incident without excess liver cancer in either
sex (Tsai et al., 2007).
In contrast to humans, rodents are highly susceptible to the
hepatotoxic, proliferative, and carcinogenic effects of TCDD (Hailey
et al., 2005; Goodman and Sauer, 1992; Kociba et al., 1978). To
summarize, the sustained AHR activation rodent liver tumor pro-
motion AOP appears to be a pathway that very likely requires ex-
ceedance of a threshold for sustained AHR activation for liver
cancers to occur in rodents (e.g. Fig. 4). In humans, increases in liver
cancer have not been observed even in highly exposed populations,
and no population level data in humans are available showing anincreased liver cancer response, even in individuals with chloracne
and obvious high exposure to DLCs. However, as is often the case for
evaluations of chemicals which lead to tumor formation in labo-
ratory animals, for regulatory purposes, assumptions are made that
potential risks to human health can be estimated from animal
studies. In many cases where there is sparse data, a default linear
no-threshold extrapolation method is used. However, in applying
this AOP for such an assessment, the extensive body of scientiﬁc
evidence clearly indicates that liver tumor promotion by DLCs only
occurs after a threshold level of sustained AHR activation is
exceeded. These thresholds also become apparent in Figs. 3B and 4.
Therefore, a quantitative application to derive an exposure guid-
ance value for humans to address the potential for tumor promo-
tion by DLCs should be based on a threshold mode of action (e.g.,
Simon et al., 2009).
7. Scientiﬁc conﬁdence in the AOP
The Bradford Hill (BH) considerations (doseeresponse, tempo-
rality, strength, consistency, speciﬁcity and biological plausibility of
the proposed association) form the basis for evaluating weight of
evidence within the U.S. Environmental Protection Agency's
Guidelines for Carcinogen Risk Assessment, the WHO/IPCS human
relevance-MOA framework, the key events/doseeresponse frame-
work (KEDRF) (Dellarco and Fenner-Crisp, 2012; Fenner-Crisp,
2012; Julien et al., 2009; Meek et al., 2003; Meek, 2008; OECD,
2013; USEPA, 2005). The BH considerations have recently been
updated and additionally tailored for AOPs by the OECD to facilitate
evaluations of KEs and KERs as well as the overall AOP (Meek et al.,
2013, 2014a, 2014b; OECD, 2014; Becker et al., 2015).
Below, we summarize the weight of evidence evaluation con-
ducted using these AOP-tailored BH considerations of biological
plausibility, essentiality and empirical evidence for the sustained
AHR activation rodent liver tumor promotion AOP.
7.1. Support for biological plausibility of the KERs
The OECD AOP guidance (OECD, 2014) for evaluation of biolog-
ical plausibility of an AOP provides this deﬁning question for
evaluating biological plausibility: “is there a mechanistic (i.e.,
structural or functional) relationship between KEup and KEdown
consistent with established biological knowledge?” Under the
OECD guidance, a high degree of conﬁdence is afforded when there
is an establishedmechanistic basis and “extensive understanding of
the KER based on extensive previous documentation and broad
acceptance.” For biological plausibility, for this AOP, the WoE for
each KER is judged to be strong, as is the WoE for the overall AOP.
All the elements in this AOP are strongly associated with the
biological steps and elements of carcinogenesis (Hanahan and
Weinberg, 2011). First, there is extensive body of mechanistic evi-
dence in support the biological plausibility of this MOA (see recent
review by Budinsky et al., 2014). Further, the relationships between
sustained AHR activation and 1) decreased intrafocal apoptosis
(KE#1); 2) increased cell proliferation (KE#2); 3) toxic hepatopathy
(KE#3); and 4) eventual tumor formation (AO) are evident from a
surfeit of published studies (e.g., Fig. 4). Moreover, overall consis-
tency with knowledge of the pathogenesis of liver tumor promo-
tion is supported by replication of events related to tumor
promotion across different laboratories and the multiple lines of
evidence for sustained AHR activation acting as a mechanism of
liver tumor promotion. Thus, the AOP is well supported by the KEs,
consistent with the biology of carcinogenesis and the events of
tumor promotion (Dietrich and Kaina, 2010; Gasiewicz et al., 2008;
Roberts et al., 1997).
The unique sensitivity of the female rat response suggests a
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MOA. Estrogen is an established co-promoter of tumorigenesis and
thus may play a role in the MOA (Graham et al., 1988; Hiraku et al.,
2001; Lucier et al., 1991; Vickers and Lucier, 1996; Vickers et al.,
1989). Crosstalk between the AHR pathway and the estrogen re-
ceptor pathway may also be a contributing factor (Matthews and
Gustafsson, 2006). Such receptor mediated cross talk is consistent
with the sustained AHR MOA.
7.2. Support for essentiality of KEs
The deﬁning question contained in the OECD AOP guidance
(OECD, 2014) for evaluation of essentiality is “are downstream KEs
and/or the AO prevented if an upstream KE is blocked?” Overall, the
evidence in support of essentiality for sustained AHR activation, the
MIE, is strong. There is direct evidence of essentiality from the stop-
exposure group in the cancer bioassay; the 100 ng/kg/d dose of
TCDDwas stopped after 30 weeks and at the 2-year termination, no
statistically signiﬁcant increase in tumor frequency was observed
(NTP, 2006a; NTP, 2006b; NTP, 2006c). This observation also in-
dicates that theMIE of sustained AHR activation requiresmore than
30weeks of continuous exposure and is consistent with the general
onset of hepatopathy around the same time (Hailey et al., 2005).
Additional support for essentiality comes from studies that show
that KEs fail to occur when AHR activity is lost through mutation,
polymorphism or knockdown (Gasiewicz et al., 2008). Further-
more, the loss of AHR responsivity to ligand-activation has been
conﬁrmed in reduction and/or loss of ligand-mediated gene tran-
scription and resistance to TCDD-induced toxicity (Harrill et al.,
2013). Conversely, constitutive AHR activity in mice increased the
incidence of tumors and hepatotoxicity (Andersson et al., 2002;
Brunnberg et al., 2006; Chopra and Schrenk, 2011; Moennikes
et al., 2004).
7.3. Empirical evidence
The OECD AOP guidance (OECD, 2014) for evaluation of empir-
ical evidence focuses on doseeresponse, temporality and incidence
concordance. Deﬁning questions include: “Does the empirical evi-
dence support that a change in KEup leads to an appropriate change
in KEdown? Does KEup occur at lower doses and earlier time points
than KEdown and is the incidence of KEup > than that for KEdown?”
Highly consistent doseeresponse relationships (KERs) along the
sequence of KEs in this AOP exhibit dose- and time-concordance.
This consistency in the concordance of both temporality and inci-
dence supports a weight of evidence determination of high for the
empirical evidence underpinning this AOP.
When the KEs and associative events are placed in sequential
order based on dose and temporality, the doseeresponse slopes
from Hill doseeresponse model ﬁts of the data increase in value.
Thus, the later KEs occur with a steeper slope than early KEs and the
number of KEs observed increases as a function of dose and time
(Table 2) (Simon et al., 2009; Budinsky et al., 2014).
Induction of xenobiotic metabolizing enzymes is one the earliest
and most sensitive responses to AHR activation (Budinsky et al.,
2010; Silkworth et al., 2005). Xenobiotic metabolizing enzyme in-
duction reﬂects acute transcriptional and proteomic changes that
are more aligned with the concept of a pre-MIE and thus provides
an associative event for AHR activation. Since measurable enzyme
induction persists for at least one year, we used the AUC of a
biomarker for this enzyme induction as ameasure of sustained AHR
activation. Both Hill equation coefﬁcients and half maximal con-
centrations increase with increasing values of sustained AHR acti-
vation and reﬂect dose-dependent transitions as KEs occur at the
various levels of biological organization (Simon et al., 2009;Budinsky et al., 2014).
Table 2, the doseeresponse temporality table, depicts the KEs
increasing in both dose and time (Meek et al., 2013; Simon et al.,
2014). This table is an essential requirement of the human rele-
vance MOA framework and is recommended in the OECD AOP
guidance (OECD, 2014). Here, the value of the sustained AHR acti-
vation index has been provided for each doseetime combination.
One can easily see the increase in sustained AHR activation due to
the increase in dose going down the table and the increase in
duration going across the table.
The need for AHR activation for a sustained period of time, i.e.
temporal concordance, is supported by the stop-exposure group in
the TCDD cancer bioassay, which showed that when the adminis-
tration of 100 ng/kg/d TCDD was stopped after 30 weeks, a statis-
tically signiﬁcant increase in tumor frequency was not observed
(NTP, 2006a). This observation also indicates that the AHR activa-
tion needs to be sustained for more than 30 weeks for KE#2 to
occur (Hailey et al., 2005).7.4. Discussion of likelihood of alternative modes of action
Alternative MOA(s) or KEs and KE elements can be examined to
help ascertain the conﬁdence in the MOA considered most likely
(Boobis et al., 2006, 2008, 2009; Cohen et al., 2003; Cohen et al.,
2004; Julien et al., 2009; Meek et al., 2003; Meek, 2008; Seed
et al., 2005; Sonich-Mullin et al., 2001; USEPA, 2005).
One such alternative MOA would be that DLCs act to produce
liver tumors in rodents by a mutagenic mechanism. However, there
is substantial evidence that DLCs are neither mutagenic nor geno-
toxic compounds and thus do not act by a mutagenic MOA (Bock
and Kohle, 2005; Dragan and Schrenk, 2000; Knerr et al., 2006;
Poland and Glover, 1979; Randerath et al., 1990; Schwarz et al.,
2000; Turteltaub et al., 1990; Wassom et al., 1977; Whysner and
Williams, 1996).
Effects on gap junctions or induction of oxidative stress are two
other potential mechanisms. TCDD disrupts normal gap junction
activity and intercellular communication in rat primary hepato-
cytes and WB-344 cells (Andrysík et al., 2013; Bager et al., 1997;
Herrmann et al., 2002; Weiss et al., 2008). Further research is
needed to understand the contribution of this mechanism to DLC-
induced rodent liver tumor formation. Oxidative stress appears less
likely as an alternativeMOA andmay be a late-occurring associative
event due to continued high activity of phase 1 mixed function
oxidases and accompanying cytotoxicity.
In summary, the WoE in support of sustained AHR activation
leading to changes in cellular growth homeostasis and eventually
promotion of liver tumors in rodents is strong. TheWoE supporting
the alternative MOAs is much weaker.8. Discussion: applications of this AOP
The OECD guidance for AOP development (OECD, 2013) suggests
a number of potential uses for AOPs. These include 1) category
formation for read-across, 2) integrated approaches for testing and
assessment 3) development or reﬁnement of test methods such as
OECD test guidelines and 4) hazard identiﬁcation (classiﬁcation/
labeling) and risk assessment. The use of a speciﬁc AOP for any one
or more of these applications depends on scientiﬁc conﬁdence in
the AOP for each speciﬁc use. An AOP can offer practical utility in
certain applications even if conﬁdence is not sufﬁcient to quanti-
tatively predict the AO from the MIE. Application of the sustained
AHR activation AOP for several applications was described in brief
in Patlewicz et al. (2015); herein we discuss the conﬁdence of this
AOP in more detail.
Table 2
Empirical evidence: application of the dose and temporal concordance AOP weight of evidence considerations for Key Events (KEs) at dose/time combination. This table is based on NTP (2006a), Teeguarden et al. (1999) and
Maronpot et al. (1993). The dose in the left most column shows the range of average liver concentration (ng/kg) from 14 weeks to 2 years from the TCDD bioassay. The number in parentheses is the administered gavage dose in
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To date, no quantitative models have been developed to predict
the adverse outcome from AHR activation by ligand binding. With
the exception of DLCs, PCDDs, PCDFs and co-planar PCBs, this
predictive capability is highly uncertain for the plethora of AHR
ligands. For example, indole 3-carbinol is an AHR ligand occurring
in cruciferous vegetables and acts as a cancer chemopreventive
agent. In the stomach, indole 3-carbinol forms 3,3-
diinolylmethane, a potent AHR ligand that has shown promise for
preventing tumor reoccurrence in humans (Banerjee et al., 2011).
Dietary administration of indole-3-carbinol for 23 weeks inhibited
tumor formation in rats initiated with diethylnitrosamine (Tanaka
et al., 1990). However, also in diethylnitrosamine-initiated rats,
prolonged indole 3-carbinol administration (>26 weeks) increased
the progression of altered hepatic foci to hepatocellular adenomas
(Yamamoto et al., 2013). A recent NTP 2-year cancer bioassay failed
to demonstrate indole 3-carbinol as a liver tumor promoter in fe-
male rats (NTP, 2014). Furthermore, endogenous AHR ligands and
naturally occurring exogenous ligands occurring in foods have
cancer-preventive properties and likely contribute to a relatively
high level of AHR activation activity in human blood (Connor et al.,
2008; Navarro et al., 2009, 2011; Peterson et al., 2009; Wincent
et al., 2009). These naturally occurring and endogenous ligands
induce both their own metabolism and that of other AHR ligands
through increased induction of xenobiotic metabolizing enzymes.
The transient metabolic increase may be one aspect of the pre-
ventive effect against sustained AHR activation that would lead to
KEs related to liver tumor promotion.
Neither binding of ligand to the AHR nor short-term transcrip-
tional changes and cellular responses are sufﬁcient to produce liver
tumors in rats. Strains of rats that show resistance towards the toxic
and carcinogenic effects of DLCs express different genomic proﬁles
outside of the conserved core battery response (Boutros et al., 2011;
Yao et al., 2012). Acute genomic changes do not appear to be pre-
dictive for the cancer endpoint (Fielden et al., 2011; Ovando et al.,
2010). AHR activation-induced transcriptional changes occur
within hours of ligand activation; yet the subsequent KEs and AO
require months of sustained AHR activation for tumors to occur.
Hence, the distinction between short-term and sustained activation
of the AHR is an important one and AHR activation must be sus-
tained for more than 30% of the rodent lifespan to result in tumor
promotion.
While binding of ligand to the AHR is identiﬁed as a pre-MIE,
sustained AHR activation by persistent ligands such as DLCs is
linked qualitatively and quantitatively to both downstream KEs and
the AO. These linkages notwithstanding, additional work is needed
to develop and evaluate such a prediction model before the MIE of
sustained AHR activation can be used in a quantitative prediction
model of the AO. Any prediction model based on this AOP needs to
consider the unique aspects of the AHR and its response to DLCs,
including the involvement of initiated or partially differentiated
stem cells, and such a model would need evaluation/validation for
its intended use (Cox et al., 2014; Patlewicz et al., 2015).
8.2. Using this AOP for grouping chemicals into chemical categories
for read-across
Without some measure of sustained activation, the use of pre-
MIEs for any purpose other than preliminary screening is prob-
lematic as a predictive criteria for liver tumor promotion. Evidence
clearly shows it is the combination of sustained AHR activation and
the subsequent biological changes involving complex parenchymal
and non-parenchymal cell interactions that underlie the hepato-
toxicity, the increase in cell proliferation and the apical tumorresponse. Hence, the MIE is deﬁned as sustained AHR activation,
and not simply AHR activation. In addition, the promiscuity of the
AHR and the species- and strain-speciﬁcity of the initial genomic
responses suggest that category development may prove a chal-
lenge (Denison, 2011; Dere, 2011).
8.3. Using this AOP for integrated approaches to testing and
assessment (IATA)
The most straightforward use of this AOP within an integrated
testing and assessment approach for hazard evaluationwould be to
determine the potential for a substance to activate the AHR in a
sustained manner with long-term changes in gene transcription
involving multiple cell types, which leads to increased liver cell
proliferation. An IATA decision-tree approach, for illustrative pur-
poses has been already presented by Patlewicz et al. (2015).
The initial steps in the IATA focus on evaluating molecular and
cellular events related to AHR binding and transcriptional activa-
tion using rapid and cost effective in silico or in vitro assays. Com-
pounds found to be inactive in such assays would not proceed
forward into further testing.
At the present time, there is insufﬁcient understanding to
permit the use transcription proﬁling as a metric of sustained AHR
activation to quantitatively predict development of rat liver foci and
liver tumors. Therefore, the IATA proposes that substances found to
be active in the AHR mechanistic assays be subjected to a decision
framework for further evaluating the potential to act as rodent liver
tumor promoter. For example, a subchronic study, utilizing an
appropriate dosing regimen, may be able to rule-in or rule-out the
substance's ability to trigger the critical histological components of
hepatopathy (Hailey et al., 2005). Or a rodent liver initiation-
promotion assay could be considered, though interpretation can
be challenging, given that indole-3-carbinol has been reported to
inhibit, and also to enhance, development of liver tumors in initi-
ated animals, whereas in the recent, more deﬁnitive 2-year rodent
study indole-3-carbinol was negative for liver tumors (Tanaka et al.,
1990; Yamamoto et al., 2013; NTP, 2014). Patlewicz et al. (2015) also
illustrate how exposure information can be used in conjunction
with the AOP to inform IATA decisions.
8.4. Using this AOP to inform test method development or
reﬁnement
An IATA consisting of a suite of in vitro and in vivo (e.g., sub-
chronic) assays to predict hepatopathy, a complex histological
response, may be needed to differentiate AHR ligands with and
without liver tumor promotion potential. Theoretically, it may be
plausible to consider using a combination of AHR-binding, AHR-
transcriptional activation and rat liver initiation-promotion assays
to develop a prediction model for sustained AHR activation-
induced rat liver tumors. Therefore, within the OECD test guide-
lines program, it may be worthwhile to consider developing per-
formance criteria that could be applied to judge the scientiﬁc
quality and reliability of in vitro AHR-binding and transactivation
assays, liver stem cell assays, as well as a validated test guideline for
a rat liver tumor (hepatic foci) initiation-promotion assay.
8.5. Taxonomic applicability: using this AOP for screening-level
evaluations of hazard and risks to humans
Over the last 15e20 years, screening-level hazard and risk
evaluations have commonly used the World Health Organization
International Programme on Chemical Safety (WHO/IPCS) TEFs for
DLCs (Van den Berg et al., 2006). To be assigned a TEF, a compound
must 1) show a structural relationship to the PCDDs and PCDFs; 2)
R.A. Becker et al. / Regulatory Toxicology and Pharmacology 73 (2015) 172e190184bind to the AHR; 3) elicit AHR-mediated biochemical and toxic
responses; and 4) be persistent and accumulate in the food chain.
The advantage of the TEF approach is that the TEQ can be deﬁned by
the sum of the products of the concentration of each compound
multiplied by its TEF. However, a wide variety of structurally
diverse, non-dioxin-like naturally occurring chemicals in vegeta-
bles, fruits, teas, etc. can also bind to, and activate, the AHR (Connor
et al., 2008; Navarro et al., 2009, 2011; Peterson et al., 2009). Thus,
what is not clear is whether substances with low TEFs would be
expected to act in vivo in a manner similar to these naturally
occurring substances or in a manner more akin to TCDD. Non-
dioxinelike AHR ligands can increase or decrease the toxicity of
2,3,7,8-TCDD and related compounds (Van den Berg et al., 2006).
Therefore, hazard or risk assessments relying on theWHO-IPCS TEF
approach need to be appropriately caveated. Similar challenges are
faced in using this AOP for conducting screening level hazard or risk
evaluations for human health.
At a number of levels of biological organization, differences exist
between the human and rodent AHR. Considering toxicodynamics,
the human AHR binding afﬁnity is an order of magnitude or more
lower than that in rodents that is generally correlated with reduced
sensitivity in human hepatocytes relative to rats (Black et al., 2012;
Budinsky et al., 2010; Connor and Aylward, 2006). In addition, these
species differences include AHR binding afﬁnity, different recruit-
ment of co-regulatory proteins, and different patterns of gene
regulation (Black et al., 2012; Budinsky et al., 2010; Carlson et al.,
2009; Connor and Aylward, 2006; Dere et al., 2011; Flaveny et al.,
2010). Considering toxicokinetics, TCDD tissue concentrations
required to induce hepatic enzyme induction in humans are higher
than those that elicit similar responses in rodents or non-human
primates (Abraham et al., 2002; Coenraads et al., 1999; Kim et al.,
2009; Lambert et al., 2006; Schrenk et al., 1995; Silkworth et al.,
2005; Sutter et al., 2010; Tang et al., 2008; Xu et al., 2000). In
terms of the whole organism, a minimal increase in CYP1A activity
can be observed at lipid-normalized blood concentrations less than
1000 ppt in humans (Abraham et al., 2002; Guzelian et al., 2006).
The corresponding adipose concentration in rats corresponding to a
minimal increase in CYP1A activity would be about 100 ppt in lipid,
consistent with earlier work showing rats are about an order of
magnitude more sensitive than humans (Budinsky et al., 2014).
Mice transfected with the human AHR are less responsive to dioxin
than mice carrying the wild-type AHR (Flaveny et al., 2009). In
human primary cell lines, dioxin-mediated changes in gene tran-
scription also require higher concentrations than those in rodents
(Budinsky et al., 2010; Haarmann-Stemmann et al., 2007; Kim et al.,
2009; Schrenk et al., 1995; Uno et al., 2009; Westerink et al., 2008;
Silkworth et al., 2005; Xu et al., 2000).
Table 3 summarizes the qualitative concordance of KEs in the
AOP between rats and humans. To the extent humans have beenTable 3
Concordance of KEs in the AOP between rats and humans for the purpose of assessing h
Key Event Pre-MIE and MIE KE#1 KE#2














Yes; occurs in vivo and
in vitro in both species;
observed as increases in
xenobiotic metabolizing
enzymes (e.g., CYP1A)
Yes but limited; occurs
in vitro in cells of human
origin, but in vivo data
from humans is lacking
Has not b
in highly e
humansinadvertently, accidentally, or intentionally exposed to TCDD, no
evidence of increased liver cancer or even liver injury have been
observed, consistent with rats being more sensitive than humans.
Given that tumorigenic responses in rodents only occur when AHR
activation is sustained for a period approximating 30% of the life-
span, and the steep slopes corresponding to responses elicited
when this apparent threshold of AHR activation is exceeded, risk
assessments for humans using this AOP should employ a threshold
model.
As noted above, binding to the AHR is insufﬁcient to infer activity
leading to the adverse outcome of liver tumors. Moreover, there is
considerable scientiﬁc debate as to whether the rat liver tumori-
genic responses induced by TCDD are relevant endpoints for human
health. WHO indicates that cancer may not be the most sensitive
response in either humans or animals and EPA's latest assessment is
based on non-cancer effects in humans (sperm deﬁcits among
young males exposed between the ages of 1e9 and increased TSH
levels in 72-hour neonates born of Seveso mothers with elevated
serum TCDD concentrations). Nonetheless, the utility of the AOP is
the identiﬁcation and ordering of effects, demonstration of dos-
eeresponse concordance and illustrating that rodent liver tumor
promotion by sustained AHR is a threshold phenomenon.9. Conclusions
Many excellent reviews and an extensive database of published
research provide the foundation for this AOP (e.g., Budinsky et al.,
2014). This case study provides a systematic construction of the
AOP according to the OECD template, drawing from this extensive
body of scientiﬁc studies. When one considers the amount of in-
formation on DLCs and AHR, one of the most signiﬁcant challenges
is gathering, distilling and organizing all of the relevant informa-
tion into a concise AOP that adequately reﬂects the current
knowledge and hypotheses on how sustained AHR activation leads
to tumor promotion and hepatic carcinogenesis in rodents. We fully
expect that as experience is gained in developing and applying
AOPs, this AOP and its applications will evolve and improve. More
data regarding doseeresponse, species sensitivity, and different
AHR ligands, that provide additional insight into KEs, associative
events and/or modulating factors will certainly strengthen the AOP.
In addition, employment of a consistent, structured scientiﬁc con-
ﬁdence framework to evaluate AOPs (OECD, 2014; Becker et al,
2014; Patlewicz et al., 2013, 2015) will help to document and
communicate the evidence in support of KEs, methods to measure
KEs, KERs, and prediction models. Users of AOPs can then make
more informed decisions regarding which applications of a given
AOP can be conﬁdently undertaken (Patlewicz et al., 2015).uman relevance (adapted from Budinsky et al., 2014).
KE#3 AO
thy Alterations in Cellular
Proliferation/Hyperplasia
Adverse Outcome: Hepatocellular





Plausible but weak (e.g., highest
relative risk in highest exposure
human cohorts for all cancers
combined is 1.4) (WHO IPCS, 1998))
een observed
xposed
No evidence in humans Evidence in humans largely negative
(e.g., no evidence of increased hepatic
tumors among former trichlorophenol
workers who were exposed to TCDD
(Collins et al., 2009))
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